Weight Management

The phase 3 study will advance the safety findings of survodutide reported in the phase 2 study to aid overweight and obesity.

Consumerization of health care solutions is connected to a growing desire of patients to have accessible health care/health data and an individualized care experience.

Investigators aimed to determine whether liraglutide, an anti-obesity medication, could impact the learning process for individuals who had reduced insulin sensitivity due to obesity.

Most participants who received retatrutide lost a considerable amount of body weight; however, individual results varied given the diversity of obesity.

Guidelines from the American Academy of Pediatrics recommend treating obesity as a chronic illness.

Session at NACDS Total Store Expo discusses how pharmacies can leverage their accessibility to decrease diet-related diseases through health and wellness.

Despite the low uptake of healthy lifestyle behaviors to achieve 5% weight loss or greater, the probability of weight loss increased among individuals with higher initial BMI.

Individuals who restrict their eating to between 12 pm and 8 pm daily lost more weight than those who reduced overall calorie intake for type 2 diabetes.

A new study indicates that adults with obesity or who are overweight with weight-related comorbidities can help manage their weight with lifestyle changes in conjunction with specified treatment.

Consuming a vegetarian diet lowered LDL-C, HbA1C, and body weight when compared to a usual diet, but did not significantly affect systolic blood pressure levels.

Researchers recommend reducing soft drink consumption and increasing physical activity to begin minimizing this widespread issue.

Phenotype-based interventions are individualized treatment plans that consider genetic and phenotypic characteristics instead of general restricted eating or exercise management.

Patients with type 2 diabetes receiving once-weekly insulin icodec were more likely to reach a hemoglobin A1C level below 7% compared to those who received once-daily insulin analogues.

Despite the surge in new diabetes cases, the treatment options in in children remain limited.

Chemotherapy may increase inflammatory biomarkers that can impact the diversity of the gut microbiome, leading to serious anthropomorphic changes among women treated for early-stage breast cancer.

Study shows equivalent overall survival among younger adults with acute lymphoblastic leukemia aged 15 to 29 and older adults aged 30 to 50 with normal BMI.

Pharmaceuticals are a critical and often lifesaving tool for managing disease, but we will never solve our chronic disease crisis through a mindset of mere management.

The results of the study were presented at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, California and were also published in The Lancet.

Pharmacists can address the needs of health care consumers earlier in the care journey by building interpersonal relationships and community trust, as well as by leading institutional and public policy reform.

Research notes that modifiable lifestyle factors, such as overconsumption of food and vitamin deficiency, can affect pregnancy.

Available pharmacological therapies have shown high efficacy in achieving weight loss.

Individuals administered oral semaglutide 50 mg achieved a statistically significant weight loss of approximately 17.4% after 68 weeks, according to Novo Nordisk.

Eating regimen shows many health benefits, but the diet may not be appropriate for all patients.

The use of semaglutide for adolescents was included in recent pediatric guidelines, though there are few studies assessing the drug in this patient population.

Weight loss that began as far as 2 years before a lung cancer diagnosis was associated with a risk of cancer.

At least 150 minutes per week of moderate intensity aerobic activity, or 75 minutes of vigorous intensity aerobic activity found to improve outcomes in patients with flu or pneumonia.

Options abound, but pharmacists should address barriers to prevent inequities for patients when they seek treatment.

BI 456906 activates the GLP-1 and glucagon receptors that help to control metabolic function, and could potentially offer clinically relevant benefits for those living with obesity or overweight without type 2 diabetes.

An increase in the use of GLP-1 agonists for weight loss is affecting patients with diabetes who rely on these medications.

Nearly 18-times more patients on trizepatide 15 mg achieved a body weight reduction of 15% or more compared to placebo.